Published on 24 June 2022
A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
Author(s): Federico J Piñeiro, Pharm, MPH, Fernández Argüelles Rogelio Alberto, Pharm, PhD
AstraZeneca, Big Pharma, biosimilars, chiral switch, esomeprazol, generics
DOI: 10.5639/gabij.2022.1102.011
8.660 views